|
Statistical parameters characterizing the results obtained from Kaplan-Meier survival curves. Characterization of Dementia Incidence in the Statin Groups and CV Comparator |
||||||||
| Dementia cases |
Time to incidence for dementia cases (months) |
Time to end of study for non-dementia cases (months) |
||||||
|
|
||||||||
| Drug |
Sample size (n) |
n |
% |
Mean |
SD |
Mean |
SD |
Model 3: HR for incidence of dementia vs CV (95% CI) |
|
|
||||||||
| CV |
394 739 |
3359 |
0.85 |
19.8 |
8.0 |
30.3 |
8.6 |
|
| Atorvastatin |
53 869 |
275 |
0.51 |
19.5 |
7.7 |
23.9 |
11.6 |
0.91 (0.80–1.02) |
| Lovastatin |
54 052 |
439 |
0.81 |
19.1 |
7.9 |
29.7 |
8.1 |
0.95 (0.86–1.05) |
| Simvastatin |
727 128 |
2647 |
0.36 |
19.3 |
7.8 |
29.1 |
8.0 |
0.46 (0.44–0.48) |
|
CV, cardiovacular. Column 1, medication group; column 2, sample size; column 3, number of dementia cases recorded during the course of the analytic period; column 4, percentage of dementia cases (calculated by dividing the value in column 3 by that in column 2); columns 5 and 6, number of months between start of the analytic period and incidence of dementia, and standard deviation (SD); columns 7 and 8, number of months between start of the analytic period and point at which subjects not receiving a diagnosis of dementia were censored due to the end of the analytic period, and SD. Hazard ratio for incidence of dementia based on the results from model 3 (Table 2). | ||||||||
Wolozin et al. BMC Medicine 2007 5:20 doi:10.1186/1741-7015-5-20 |
||||||||